{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T04:04:25Z","timestamp":1747109065272,"version":"3.40.5"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Pregnant women with obesity are at increased risk of a multitude of complications of pregnancy and adverse perinatal outcomes. The risk of some of these complications, such as neural tube defects or preeclampsia, may be mitigated by some medications. Other complications, such as diabetes, venous thromboembolism, and infections, require treatment with medications. Given the changes in pharmacokinetics and pharmacodynamics during pregnancy, which is further enhanced by obesity, the optimal medication and its dose is often researched. This chapter further explores the different complications and common medications that women with obesity are likely to require.<\/jats:p>","DOI":"10.1097\/grf.0000000000000584","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T23:09:06Z","timestamp":1607641746000},"page":"214-225","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Medications for Pregnant Women With Obesity: Special Considerations"],"prefix":"10.1097","volume":"64","author":[{"given":"LINDSAY","family":"MAGGIO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"R2-20250512","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ajog.2008.04.021","article-title":"Maternal obesity and risk of neural tube defects: a metaanalysis","volume":"198","author":"Rasmussen","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"RR-14","key":"R3-20250512","first-page":"1","article-title":"Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/tera.10060","article-title":"Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States","volume":"66","author":"Williams","year":"2002","journal-title":"Teratology"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10654-004-2253-z","article-title":"Body mass index and serum folate in childbearing age women","volume":"19","author":"Mojtabai","year":"2004","journal-title":"Eur J Epidemiol"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1080\/14767058.2018.1440546","article-title":"Obesity in pregnancy: a comparison of four national guidelines","volume":"32","author":"Vitner","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/AOG.0000000000001211","article-title":"ACOG Practice Bulletin No 156: Obesity in pregnancy","volume":"126","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R8-20250512","first-page":"e1","article-title":"ACOG Practice Bulletin No. 202: Gestational hypertension and preeclampsia","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/14767058.2017.1399117","article-title":"Body mass index and the risk of hypertensive disorders of pregnancy: the great obstetrical syndromes (GOS) study","volume":"32","author":"Gasse","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R10-20250512","first-page":"CD001059","article-title":"Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems","volume":"6","author":"Hofmeyr","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20250512","doi-asserted-by":"crossref","first-page":"110.e6","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis","volume":"216","author":"Roberge","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/AOG.0000000000002708","article-title":"ACOG Committee Opinion No. 743: Low-dose aspirin use during pregnancy","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/dme.13523","article-title":"Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis","volume":"35","author":"Alqudah","year":"2018","journal-title":"Diabet Med"},{"issue":"suppl 1","key":"R14-20250512","first-page":"S183","article-title":"14. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1097\/AOG.0000000000002960","article-title":"ACOG Practice Bulletin No. 201: Pregestational diabetes mellitus","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/AOG.0000000000002501","article-title":"ACOG Practice Bulletin No. 190: Gestational diabetes mellitus","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00404-015-3692-3","article-title":"Safety of insulin analogs during pregnancy: a meta-analysis","volume":"292","author":"Lv","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2337\/diab.46.2.265","article-title":"Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group","volume":"46","author":"Anderson","year":"1997","journal-title":"Diabetes"},{"key":"R19-20250512","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/dmd.109.031245","article-title":"Pharmacokinetics of metformin during pregnancy","volume":"38","author":"Eyal","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R20-20250512","doi-asserted-by":"crossref","first-page":"F488","DOI":"10.1136\/archdischild-2015-309602","article-title":"Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes","volume":"101","author":"Wouldes","year":"2016","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R21-20250512","doi-asserted-by":"crossref","first-page":"e109985","DOI":"10.1371\/journal.pone.0109985","article-title":"Efficacy and safety of oral antidiabetic drugs in comparison to insulin in treating gestational diabetes mellitus: a meta-analysis","volume":"9","author":"Poolsup","year":"2014","journal-title":"PLoS One"},{"key":"R22-20250512","doi-asserted-by":"crossref","first-page":"h102","DOI":"10.1136\/bmj.h102","article-title":"Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis","volume":"350","author":"Balsells","year":"2015","journal-title":"BMJ"},{"key":"R23-20250512","doi-asserted-by":"crossref","first-page":"e0182488","DOI":"10.1371\/journal.pone.0182488","article-title":"Comparison of glyburide and insulin in the management of gestational diabetes: a meta-analysis","volume":"12","author":"Song","year":"2017","journal-title":"PLoS One"},{"key":"R24-20250512","doi-asserted-by":"crossref","first-page":"9804708","DOI":"10.1155\/2019\/9804708","article-title":"Comparative efficacy and safety of metformin, glyburide, and insulin in treating gestational diabetes mellitus: a meta-analysis","volume":"2019","author":"Guo","year":"2019","journal-title":"J Diabetes Res"},{"key":"R25-20250512","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/dom.13275","article-title":"Safety of non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: a cohort study","volume":"20","author":"Cea-Soriano","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R26-20250512","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/clpt.2009.5","article-title":"Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice","volume":"85","author":"Hebert","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R27-20250512","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/AOG.0000000000002833","article-title":"ACOG Practice Bulletin No. 199: use of prophylactic antibiotics in labor and delivery","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R28-20250512","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1213\/ANE.0b013e31821fff74","article-title":"Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection","volume":"113","author":"Toma","year":"2011","journal-title":"Anesth Analg"},{"key":"R29-20250512","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1467-789X.2007.00397.x","article-title":"Maternal obesity and risk of cesarean delivery: a meta-analysis","volume":"8","author":"Chu","year":"2007","journal-title":"Obes Rev"},{"key":"R30-20250512","first-page":"299","article-title":"Maternal obesity and risk of postcesarean wound complications","volume":"31","author":"Conner","year":"2014","journal-title":"Am J Perinatol"},{"key":"R31-20250512","first-page":"CD003577","article-title":"Techniques and materials for skin closure in caesarean section","volume":"11","author":"Mackeen","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R32-20250512","first-page":"CD007482","article-title":"Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section","volume":"10","author":"Smaill","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R33-20250512","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/sur.2013.9999","article-title":"Clinical practice guidelines for antimicrobial prophylaxis in surgery","volume":"14","author":"Bratzler","year":"2013","journal-title":"Surg Infect"},{"key":"R34-20250512","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/AOG.0b013e31820b95e4","article-title":"Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery","volume":"117","author":"Pevzner","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R35-20250512","doi-asserted-by":"crossref","first-page":"415.e1","DOI":"10.1016\/j.ajog.2015.05.030","article-title":"Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women","volume":"213","author":"Swank","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R36-20250512","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0000000000000789","article-title":"Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial","volume":"125","author":"Maggio","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R37-20250512","doi-asserted-by":"crossref","first-page":"541.e1","DOI":"10.1016\/j.ajog.2015.06.034","article-title":"Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery","volume":"213","author":"Young","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R38-20250512","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/jcph.851","article-title":"Population pharmacokinetics of cefazolin in serum and adipose tissue from overweight and obese women undergoing cesarean delivery","volume":"57","author":"Grupper","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R39-20250512","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejogrb.2017.01.022","article-title":"Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section?","volume":"210","author":"Kram","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R40-20250512","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/AOG.0000000000001064","article-title":"Obstetric surgical site infections: 2 grams compared with 3 grams of cefazolin in morbidly obese women","volume":"126","author":"Ahmadzia","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R41-20250512","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa1602044","article-title":"Adjunctive azithromycin prophylaxis for cesarean delivery","volume":"375","author":"Tita","year":"2016","journal-title":"N Engl J Med"},{"key":"R42-20250512","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jama.2017.10567","article-title":"Effect of post-cesarean delivery oral cephalexin and metronidazole on surgical site infection among obese women: a randomized clinical trial","volume":"318","author":"Valent","year":"2017","journal-title":"JAMA"},{"key":"R43-20250512","first-page":"e1","article-title":"ACOG Practice Bulletin No. 188: Prelabor rupture of membranes","volume":"131","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R44-20250512","first-page":"178","article-title":"Preterm premature rupture of the membranes","volume":"101","author":"Mercer","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R45-20250512","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jama.1997.03550120049032","article-title":"Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network","volume":"278","author":"Mercer","year":"1997","journal-title":"JAMA"},{"key":"R46-20250512","doi-asserted-by":"crossref","first-page":"144.e1","DOI":"10.1016\/j.ajog.2019.03.009","article-title":"Azithromycin vs erythromycin for the management of preterm premature rupture of membranes","volume":"221","author":"Navathe","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"R47-20250512","doi-asserted-by":"crossref","first-page":"c3428","DOI":"10.1136\/bmj.c3428","article-title":"Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta-analyses","volume":"341","author":"McDonald","year":"2010","journal-title":"BMJ"},{"key":"R48-20250512","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1001\/jama.2013.6295","article-title":"Maternal obesity and risk of preterm delivery","volume":"309","author":"Cnattingius","year":"2013","journal-title":"JAMA"},{"key":"R49-20250512","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/GRF.0000000000000175","article-title":"Delivery of the obese gravida","volume":"59","author":"Faucett","year":"2016","journal-title":"Clin Obstet Gynecol"},{"key":"R50-20250512","doi-asserted-by":"crossref","first-page":"600.e1","DOI":"10.1016\/j.ajog.2009.06.030","article-title":"Latency and infectious complications after preterm premature rupture of membranes: impact of body mass index","volume":"201","author":"Joy","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R51-20250512","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1097\/AOG.0000000000003668","article-title":"Prevention of group B streptococcal early-onset disease in newborns: ACOG Committee Opinion, Number 797","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"RR-10","key":"R52-20250512","first-page":"1","article-title":"Prevention of perinatal group B streptococcal disease\u2014revised guidelines from CDC, 2010","volume":"59","author":"Verani","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R53-20250512","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/01443615.2018.1552670","article-title":"Maternal obesity and the risk of group B streptococcal colonisation in pregnant women","volume":"39","author":"Manzanares","year":"2019","journal-title":"J Obstet Gynecol"},{"issue":"pt 1","key":"R54-20250512","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/01.AOG.0000124568.71597.ce","article-title":"Maternal morbidity associated with vaginal versus cesarean delivery","volume":"103","author":"Burrows","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R55-20250512","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/OGX.0000000000000469","article-title":"Body mass index 50\u2009kg\/m2 and beyond: perioperative care of pregnant women with superobesity undergoing cesarean delivery","volume":"72","author":"Smid","year":"2017","journal-title":"Obstet Gynecol Surv"},{"key":"R56-20250512","first-page":"CD001067","article-title":"Antibiotic regimens for postpartum endometritis","volume":"2","author":"Mackeen","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R57-20250512","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"R58-20250512","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R59-20250512","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2005.11.008","article-title":"Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality","volume":"194","author":"James","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R60-20250512","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.chest.2016.05.021","article-title":"Risks of venous thromboembolism after cesarean sections: a meta-analysis","volume":"150","author":"Blondon","year":"2016","journal-title":"Chest"},{"key":"R61-20250512","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/AOG.0000000000000564","article-title":"Pregnancy-related mortality in the United States, 2006-2010","volume":"125","author":"Creanga","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R62-20250512","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/AOG.0000000000001579","article-title":"National Partnership for Maternal Safety: consensus bundle on venous thromboembolism","volume":"128","author":"D\u02bcAlton","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"suppl","key":"R63-20250512","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"key":"R65-20250512","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1471-0528.2007.01622.x","article-title":"Antenatal pulmonary embolism: risk factors, management and outcomes","volume":"115","author":"Knight","year":"2008","journal-title":"BJOG"},{"key":"R66-20250512","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.thromres.2016.06.001","article-title":"Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: rationale and design of the highlow study, a randomised trial of two doses","volume":"144","author":"Blecker","year":"2016","journal-title":"Thromb Res"},{"key":"R67-20250512","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/jp.2015.130","article-title":"A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women","volume":"36","author":"Stephenson","year":"2016","journal-title":"J Perinatol"},{"key":"R68-20250512","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/AOG.0000000000000873","article-title":"Enoxaparin dosing after cesarean delivery in morbidly obese women","volume":"125","author":"Overcash","year":"2015","journal-title":"Obstet Gynecol"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:18:36Z","timestamp":1747063116000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000584","relation":{},"ISSN":["0009-9201"],"issn-type":[{"type":"print","value":"0009-9201"}],"subject":[],"published":{"date-parts":[[2020,12,9]]}}}